新的药物组合Enhertu加上pertuzumab可极大地促进HER2-阳性乳腺癌的存活。 New drug combo Enhertu plus pertuzumab significantly boosts survival in HER2-positive breast cancer.

一种新的药物组合,Enhertu+pertuzumab,与标准治疗相比,在治疗HER2-阳性转移性乳腺癌方面有了显著改进。 A new drug combination, Enhertu plus pertuzumab, has shown significant improvements in treating HER2-positive metastatic breast cancer compared to standard treatments. 这种综合疗法明显提高了病人的无累进性存活率,标志着十多年来首次出现这种改善。 This combination therapy was found to notably increase progression-free survival in patients, marking the first such improvement in over a decade. 在所有乳腺癌病例中,约15-20%的人患有HER2-呈阳性乳癌。 HER2-positive breast cancer affects about 15-20% of all breast cancer cases.